These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 22989373)

  • 1. Benefits of pharmaceutical innovation: the case of simvastatin in Canada.
    Thanh NX; Chuck AW; Ohinmaa A; Jacobs P
    Int J Technol Assess Health Care; 2012 Oct; 28(4):390-7. PubMed ID: 22989373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
    Sedjo RL; Cox ER
    Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
    Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
    CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study.
    Wilhelmsen L; Welin L; Odén A; Björnberg A
    Eur J Health Econ; 2010 Apr; 11(2):177-84. PubMed ID: 19495819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disability benefit coverage and program interactions in the working-age population.
    Rupp K; Davies PS; Strand A
    Soc Secur Bull; 2008; 68(1):1-30. PubMed ID: 18837269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
    N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions].
    Szucs TD; Lüscher TF; Gutzwiller F
    Schweiz Med Wochenschr; 1997 Nov; 127(44):1819-23. PubMed ID: 9446200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
    Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
    Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
    Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
    Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
    Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
    Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
    Zubaid M; Shakir DK; Bazargani N; Binbrek A; Gopal R; Al-Tamimi O; Bakir S
    J Cardiovasc Med (Hagerstown); 2008 Jul; 9(7):688-93. PubMed ID: 18545068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use over time of statins in coronary patients in an Italian tertiary referral center.
    Gaspardone A; Proietti I; Altamura L; Tomai F; Versaci F; Crea F; Chiariello L; Gioffrè PA
    Ital Heart J; 2001 Nov; 2(11):848-53. PubMed ID: 11770871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
    Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS
    Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of atorvastatin over the product life cycle in the United States.
    Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.